Scott Van Wart

Posters/Presentations

1.    Wang Q, Cook SF, Van Wart SA, Mager DE, Faderl S. Population pharmacokinetic (PK)/pharmacodynamic (PD) modeling of myelosuppression in patients with hematologic malignancies for CPX-351 and standard-of-care 7+3 therapy. Poster presentation [4037] at the 60th American Society of Hematology Meeting. December 1-4, 2018, San Diego, CA, USA.

2.    Van Wart SA. Challenges and potential opportunities to better predict bioequivalence and switchability for biologics exhibiting TMDD. Session Chair and podium presentation at the 9th American Conference on Pharmacometrics. October 7-11, 2018, San Diego, CA, USA. 


3.    Cook S, Wang Q, Mager DE, Van Wart SA. Population pharmacokinetic-pharmacodynamic (PK-PD) modeling of chemotherapy-induced neutropenia (CIN) in patients treated with CPX-351. Poster presentation [W-024] at the 9th American Conference on Pharmacometrics. October 7-11, 2018, San Diego, CA, USA.


4.    Cook S, Wang Q, Mager DE, Van Wart SA Population pharmacokinetic-pharmacodynamic (PK-PD) modeling of CPX-351-induced thrombocytopenia. Poster presentation [W-025] at the 9th American Conference on Pharmacometrics. October 7-11, 2018, San Diego, CA, USA.


5.    Patel CG, Van Wart SA, Bottino D, Kalebic T, Yang H, Moharil J, Mager DE, Venkatakrishnan K. Population pharmacokinetics of MLN0264, a guanylyl cyclase C targeted antibody-drug conjugate, in patients with advanced gastrointestinal (GI) malignancies. Poster presented at American Society of Clinical Pharmacology and Therapeutics Meeting, Mar 22-24, 2018, Orlando, FL, USA.


6.    Van Wart SA, Manley A, Bhavnani SM, Tanaka K, Loh E, Rubino CM, Tzanis E, and Ambrose PG.  Population pharmacokinetics of omadacycline following intravenous (IV) or oral administration to Phase 1 subjects. Poster P1320. 26th ECCMID 2016, Amsterdam, NL.


7.    Van Wart SA, Shoaf S, Mallikaarjun S, Mager DE. Pharmacokinetic-Pharmacodynamic (PK-PD) modeling of tolvaptan and diuretic use on fluid and electrolyte balance in healthy subjects. Poster-podium presentation at the 6th American Conference on Pharmacometrics. October 4-7, 2015, Washington, DC, USA [Abstract T-04]. Awarded ISoP Quality Award for 2015. 


8.    Van Wart SA, Shoaf S, Mallikaarjun S, Mager DE. Pharmacokinetic-Pharmacodynamic (PK-PD) model for tolvaptan in hypervolemic hyponatremia. Poster presentation at the 6th American Conference on Pharmacometrics. October 4-7, 2015, Washington, DC, USA [Abstract W-06]. 


9.    Van Wart SA, Bhavnani SM, Forrest A, Jorgensen DM, Tack KJ, Ambrose PG, Rubino CM. Population pharmacokinetics of brilacidin in healthy subjects and patients with acute bacterial skin and skin structure infections. [Abstract A-038]. Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA. September 17-21, 2015.


10.    Bulik CC, Rayner CR, Hammel JP, Smith PF, Van Wart SA, Kamal MA, Smith JR, Ambrose PG, Bhavnani SM. Evaluation of pharmacokinetic-pharmacodynamic relationships for influenza symptoms and quality of life endpoints among oseltamivir-treated patients. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. September 5-9, 2014. [Abstract A-011].


11.    Van Wart SA, Melhem M, Barth J, Rubino CM, Elfring G, Northcutt V, Babiak J, Ambrose PG. Keep on Walking: Pharmacokinetic-Pharmacodynamic Analysis and Dose Selection Support for Ataluren in the Treatment of Nonsense Mutation Duchenne-Becker Muscular Dystrophy. Poster-podium presentation at the 4th American Conference on Pharmacometrics. May, 2013, Fort Lauderdale, FL, USA. [Abstract W-021] Awarded ISoP Quality Award for 2013. 


12.    Van Wart SA, Forrest A, Drusano GL, Bhavnani SM, Bulik CC, Kostrub CF, Ambrose PG, Louie A. Pharmacokinetic-pharmacodynamic analysis predicts a high probability of efficacy for plazomicin against serious infections caused by carbapenem-resistant Enterobacteriaceae. 52nd European Congress of Clinical Microbiology and Infectious Diseases. Berlin, Germany. April 27-30, 2013. [Abstract No. P 914].


13.    Van Wart SA, Melhem M, Davenport JM, Ambrose PG, Bhavnani SM, Andes DR, Craig WA, McIntyre GF, Rubino CM. Population pharmacokinetic and pharmacokinetic-pharmacodynamic target attainment analyses to support JNJ-Q2 dose selection for patients with acute bacterial skin and skin structure infections. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. September 9-12. 2012. [Abstract A-1961].

14.    Kamal MA, Van Wart SA, Rayner CR, Subramoney V, Reynolds DK, Bulik CC, Smith PF, Bhavnani SM, Forrest A. Population pharmacokinetics of oseltamivir in pediatric and adult subjects. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. September 9-12. 2012. [Abstract A-1244].

15.    Bhavnani SM, Hammel JP, Van Wart SA, Melhem M, Rubino CM, Davenport JM, McIntyre GF, Ambrose PG. Pharmacokinetic-pharmacodynamic analysis for efficacy of JNJ-Q2 using Phase 2 data from patients with acute bacterial skin and skin structure infections. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. September 9-12. 2012. [Abstract A-1962].

16.    Van Wart SA, Bhavnani SM, Jones RN, Forrest A, Bulik CC, Pfister M, Bertz RJ, Ambrose PG. Pharmacokinetic Pharmacodynamic (PK-PD) Target Attainment (TA) Analyses to Evaluate Susceptibility Breakpoints (SB) for Cefepime (CPM) in Renal Impairment. 51st InterScience Conference on Antimicrobial Agents and Chemotherapy. Chicago IL. September 17-20, 2011.

17.    Van Wart SA, Forrest A, Khariton T, Rubino CM, Bhavnani SM, Riccobene TM, Ambrose PG. Population Pharmacokinetic (PPK) Analysis of Ceftaroline (CPT) in Patients with Complicated Skin and Skin Structure Infection (cSSSI) or Community-Acquired Pneumonia (CAP). 51st InterScience Conference on Antimicrobial Agents and Chemotherapy. Chicago IL. September 17-20, 2011.

18.    Van Wart SA, Reynolds DK, Khariton T, Bhavnani SM, Rubino CM, Ambrose PG, Riccobene TM. Impact of Concomitant Medication (CM) Use on the Pharmacokinetics (PK) of Ceftaroline (CPT) in Patients with Complicated Skin and Skin Structure Infections (cSSSI) or Community-Acquired Pneumonia (CAP). 51st InterScience Conference on Antimicrobial Agents and Chemotherapy. Chicago IL. September 17-20, 2011.

19.    Bhavnani SM, Hammel JP, Van Wart SA, Reynolds DK, Forrest A, Drusano GL, Khariton T, Riccobene TM, Ambrose PG. Pharmacokinetic-Pharmacodynamic (PK-PD) Analysis for Efficacy of Ceftaroline (CPT) Fosamil in Patients with Complicated Skin and Skin Structure Infection (cSSSI). 51st InterScience Conference on Antimicrobial Agents and Chemotherapy. Chicago IL. September 17-20, 2011.

20.    Bhavnani SM, Hammel JP, Van Wart SA, Reynolds DK, Forrest A, Drusano GL, Khariton T, Riccobene TM, Ambrose PG. Pharmacokinetic-Pharmacodynamic (PK-PD) Analysis for Efficacy of Ceftaroline (CPT) Fosamil in Patients with Community-Acquired Pneumonia (CAP). 51st InterScience Conference on Antimicrobial Agents and Chemotherapy. Chicago IL. September 17-20, 2011.

21.    Bhavnani SM, Van Wart SA, Rubino CM, Khariton T, Riccobene TM, Critchley I, Ambrose PG. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment (TA) Analysis to Evaluate Susceptibility Test Interpretive Criteria for Ceftaroline (CPT) against Staphylococcus aureus (SA). 51st InterScience Conference on Antimicrobial Agents and Chemotherapy. Chicago IL. September 17-20, 2011.

22.    Van Wart SA, Ambrose PG, Rubino CM, Khariton T, Riccobene TM, Bhavnani SM. Use of Ceftaroline (CPT) against Streptococcus pneumoniae (SP): Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment (TA) Analysis to Evaluate Susceptibility Test Interpretive Criteria. 51st InterScience Conference on Antimicrobial Agents and Chemotherapy. Chicago IL. September 17-20, 2011.

23.    Tsai M, Cirincione BB, Chan J, Van Wart SA. Modeling the Time-Course of Body Weight for Subjects Given Placebo in an Obesity Trial. Presented at the Annual American College of Clinical Pharmacology Meeting. September 11-13, 2011, Chicago, IL, USA.

24.    Van Wart SA, Mallikaarjun S, Shoaf S, Mager DE. A Pooled-Analysis Approach to Develop a Population Pharmacokinetic (PK) Model for Furosemide. Presented at the 3rd American Conference on Pharmacometrics. April 4-6, 2011, San Diego, CA, USA.

25.    Van Wart SA, Tsai M, Chan J, Cirincione BB. Modeling the Time-Course of Body Weight for Subjects Given Placebo in an Obesity Trial. Presented at the 3rd American Conference on Pharmacometrics. April 4-6, 2011, San Diego, CA, USA.

26.    Xue B Melhem M, Reynolds DK, Yousef AM, Van Wart SA. Population Pharmacokinetic Analysis and Design of an Optimal Sampling Strategy for Clopidogrel. Presented at the 3rd American Conference on Pharmacometrics. April 4-6, 2011, San Diego, CA, USA.

27.    Van Wart SA, Bhavnani SM, Forrest A, Bruss J, Cass R, Ambrose PG. Population pharmacokinetics of ACHN-490 injection in healthy subjects. 48th Annual Meeting of the Infectious Disease Society of America, Vancouver, BC. October 21-24, 2010.

28.    Van Wart SA, Bhavnani SM, Jones RN, Forrest A, Pfister M, Bertz RJ, Ambrose PG. Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate susceptibility breakpoints for labeled cefepime dosing regimens. 50th InterScience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA. September 12-15, 2010. [Abstract No. A1-1375].

29.    Van Wart SA, Bhavnani SM, Chau TTH, Farrar J, Ambrose PG, Thwaites G. Population pharmacokinetics and cerebrospinal fluid penetration for fluoroquinolones in tuberculosis meningitis patients. 50th InterScience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA. September 12-15, 2010. [Abstract No. A1-057].

30.    Van Wart SA, Forrest A, Bhavnani SM, Khariton T, Riccobene TA, Reynolds DK, Ghahramani P, Ambrose PG. Population pharmacokinetics of ceftaroline in healthy and renally impaired subjects. Presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 11-14, 2009, San Francisco, CA.

31.    Van Wart SA, Pai MP, Bhavnani SM, Weigand UW, Jones RN, Ambrose PG. Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate susceptibility breakpoints for labeled ceftriaxone dosing regimens. Presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 11-14, 2009, San Francisco, CA.


32.    Okusanya OO, Hammel JP, Bhavnani SM, Van Wart SA, Forrest A, Govan JRW, Ambrose PG, Gupta R. Pharmacokinetics and pharmacokinetics-pharmacodynamics of liposomal amikacin in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA. September 12-15, 2009. [Abstract No. A1-567].

33.    Okusanya OO, Lehoux D, Van Wart SA, Deng H. Forrest A, Rafai Far A, Moeck G, Bhavnani SM, Ambrose PG, Parr TR Jr. Pharmacokinetics and pharmacokinetics-pharmacodynamics of oritavancin against Streptococcus pyogenes using data from a neutropenic murine thigh-infection model. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA. September 12-15, 2009. [Abstract No. A1 1286].

34.    Okusanya OO, Lehoux D, Van Wart SA, Rafai Far R, Forrest A, Moeck G, Bhavnani SM, Parr TR Jr, Ambrose PG. Pharmacokinetics and pharmacokinetics-pharmacodynamics of oritavancin against Staphylococcus aureus using data from a neutropenic murine thigh-infection model. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA. September 12-15, 2009. [Abstract No. A1-1287].

35.    Van Wart SA, Marathe A, Mager DE. Impact of Dose Selection and Assay Sensitivity on Target Mediated Drug Disposition (TMDD) Population Pharmacokinetic (PK) Model Parameter Estimation: A Case Study Using Interferon (IFN)–beta. Presented at the 2nd Annual American Conference on Pharmacometrics, October 3-6, 2009, Connecticut, USA.

36.    Okusanya OO, Lehoux D, Van Wart SA, Far R, Forrest A, Moeck G, Bhavnani SM, Parr TR Jr. TR, Ambrose PG. Pharmacokinetics and pharmacokinetics-pharmacodynamics of oritavancin against Staphylococcus aureus in a neutropenic murine-thigh infection model. International Society of Anti-Infective Pharmacology Meeting, Madison, Wisconsin. October 29, 2008.

37.    Ambrose PG, Forrest A, Okusanya OO, Van Wart SA, Bhavnani SM. Pharmacokinetic-pharmacodynamic target attainment of daptomycin against Staphylococcus aureus. Presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Infectious Disease Society of America, October 25-28, 2008, Washington, DC.

38.    Forrest A, Okusanya OO, Bhavnani SM, Lacza CT, Van Wart SA, Zhang S, Mortin L, Ambrose PG. PK-PD evaluation of daptomycin against S. aureus strains with increased MIC values after daptomycin exposure. Presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Infectious Disease Society of America, October 25-28, 2008, Washington, DC.

39.    Bhavnani SM, Iyer V, Hammel JP, Forrest A, Rubino CM, Van Wart SA, Prakhya A, McCollam, JS, Ambrose PG. Pharmacokinetic-pharmacodynamic oritavancin efficacy in patients with complicated skin and skin structure infection. Presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Infectious Disease Society of America, October 25-28, 2008, Washington, DC.

40.    Van Wart SA, Iyer V, Forrest A, Bhavnani SM, Ambrose PG, and Andes DA. Population pharmacokinetics of micafungin in patients with invasive Candidiasis, Candidemia, and esophageal Candidiasis. Presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Infectious Disease Society of America, October 25-28, 2008, Washington, DC.

41.    Rubino CM, Van Wart SA, Bhavnani SM, McCollam JS, Ambrose PG. Population pharmacokinetics of oritavancin. Presented at the Annual Meeting of the American College of Clinical Pharmacy, October 19-22, 2008, Louisville, KY.

42.    Van Wart S, Rubino CM, Forrest A, Okusanya OO, and Mager DE. Comparison of the performance of likelihood-based methods implemented in NONMEM® and MC-PEM/S-ADAPT to account for pharmacokinetic data below the lower limit of quantification. Presented at the 1st Annual American Conference on Pharmacometrics, March, 2008, Tucson, AZ.

43.    Van Wart S. What are the expectations of preliminary models? Podium presentation at the 7th Annual East Coast Population Analysis Group meeting, July, 2006, Baltimore, MD.

44.    Van Wart SA, Cirincione BB, Ludwig EA, Chen X, Shoaf S, Grasela TH, and Mallikaarjun S. Pharmacokinetic/pharmacodynamic model for tolvaptan in patients with congestive heart failure and/or hyponatremia. Podium Presentation at the 2006 American Society for Clinical Pharmacology and Therapeutics, Baltimore, MD.

45.    Van Wart SA, Cirincione BB, Ludwig EA, Chen X, Shoaf S, Grasela TH, and Mallikaarjun S. Pharmacokinetic/pharmacodynamic model for tolvaptan in healthy volunteers. Poster presentation at the 2006 American Society for Clinical Pharmacology and Therapeutics, Baltimore, MD. 

46.    Van Wart SA, Owen JS, Meagher AK, and Cirincione BB. Population pharmacokinetics of tigecycline in patients with complicated skin and skin-structure infections and intra-abdominal infections. Presented at the 45th annual International Conference of Antimicrobial Agents and Chemotherapeutics, December, 2005, Washington, DC.

47.    Passarell JA, Liolios K, Meagher AK, Cirincione BB, Van Wart SA, Babinchak T, and Ellis-Grosse EJ. Exposure-response analysis of the efficacy of tigecycline in patients with complicated intra-abdominal infections. Presented at the 45th annual International Conference of Antimicrobial Agents and Chemotherapeutics, December, 2005, Washington, DC.

48.    Meagher AK, Passarell JA, Liolios K, Van Wart SA, Cirincione BB, and Ambrose PG. Estimation of in vitro susceptibility breakpoints for tigecycline against Enterobacteriaceae. Presented at the 45th annual International Conference of Antimicrobial Agents and Chemotherapeutics, December, 2005, Washington, DC.

49.    Meagher AK, Passarell JA, Van Wart SA, Cirincione BB, and Ambrose PG. Estimation of in vitro susceptibility breakpoints for tigecycline against staphylococci. Presented at the 45th annual International Conference of Antimicrobial Agents and Chemotherapeutics, December, 2005, Washington, DC.

50.    Van Wart SA, Owen JS, Meagher AK, and Cirincione BB. Application of population pharmacokinetics of tigecycline in Phase 3 patients with complicated skin and skin-structure infections and intra-abdominal infections. Presented at the 2005 American Association of Pharmaceutical Scientists Annual Meeting, November, 2005, Nashville, TN.

51.    Meagher AK, Passarell JA, Cirincione BB, Van Wart SA, Liolios K, Babinchak T, Ellis-Grosse EJ, Ambrose PG. Exposure-response analysis of the efficacy of tigecycline in patients with complicated skin and skin-structure infections. Poster presentation at the 15th European Congress of Clinical Microbiology and Infectious Diseases, April, 2005, Copenhagen, Denmark.

52.    Van Wart S, Phillips L, and Grasela TH. Evaluation of the Bias and Precision of Empiric Bayesian Parameter Estimates When Applying a Phase I Model to Sparse Patient Data. Presented at the 2004 American Association of Pharmaceutical Scientists Annual Meeting, November, 2004, Baltimore, MD.

53.    Van Wart S, Bhavnani SM, Phillips L, Wikler MA, and Ambrose PG. Population Pharmacokinetics of Doripenem. Presented at the 44th annual International Conference of Antimicrobial Agents and Chemotherapy, October, 2004, Washington, DC.

54.    Ambrose PG, Phillips L, Bhavnani SM, Van Wart S, Cirincione B, Andes D and Wikler MA. Use of Pharmacokinetics-Pharmacodynamics as Decision Support for Phase 3 Dose Justification for Doripenem. Presented at the 44th annual International Conference of Antimicrobial Agents and Chemotherapy, October, 2004, Washington, DC.

55.    Van Wart S, Cirincione BB, Hirankarn S, Phillips L, Meagher A, Troy S, Owen JS. Population Pharmacokinetics Analysis of Tigecycline Data from Healthy Subjects. Presented at the 44th annual International Conference of Antimicrobial Agents and Chemotherapeutics, October, 2004, Washington, DC.

56.    Van Wart S, Ambrose PG, Nicolau DP, Anon J, and Owen JS. Pharmacokinetic Analysis of Gatifloxacin in Plasma and Sinus Exudate during Treatment of Acute Maxillary Sinusitis. Presented at the 2003 American Association of Pharmaceutical Scientists Annual Meeting, October 26-30, 2003, Salt Lake City, UT.

57.    Ambrose PG, Jones RN, Van Wart S, Owen JS, McPhee ME, Costanzo C, Bhavnani SM, and Anon J. A Novel Technique for Evaluating Antimicrobial Therapy of Acute Maxillary Sinusitis. Presented at the 43rd annual International Conference of Antimicrobial Agents and Chemotherapeutics, September 27-30, 2003, Chicago, IL.

58.    Ambrose PG, Jones RN, Gajjar DA, Van Wart S, Rubino C, Bhavnani SM, Grasela DM. Use of Monte Carlo Simulation to Evaluate the Antibacterial Activity of Garenoxacin (BMS-284756) Against Gram-Positive Bacteria. Presented at the 42nd annual International Conference of Antimicrobial Agents and Chemotherapeutics, September 27-30, 2002, San Diego, CA.

59.    Van Wart S. Diagnosing Problems Associated with Estimation of the Absorption Rate Constant for Sparsely Sampled Data. Podium presentation at the 5th Annual East Coast Population Analysis Group meeting, March 15, 2002, Baltimore, MD.

60.    Kosoglou T, Belanger B, Alton KB, Van Wart S, Patrick JE, Singer B, and Affrime MB. Eptifibatide Plasma Concentration-Response Relationship of Ex Vivo Platelet Aggregation in Patients Undergoing Coronary Angioplasty. Presented at the annual meeting of the European Society of Cardiology, August 22-26, 1998 Vienna, Austria.

Manuscripts

1.   Van Wart SA, Passier P, Mager DE, Bednasz C, Moharil J, Collins C, Meijer J, Laszlo I, Bergmann KR. Pharmacokinetic-pharmacodynamic model for ASP-7398 induced water retention in healthy subjects. Journal of Pharmacokinetics and Pharmacodynamics (In Review).

2.    Muksin M, Nanavati C, Baumgart M, Gabrail N, Van Wart SA, Mager DE, Maneval DC, Fathallah AM, Sekulovich RE. Safety and pharmacokinetics of docetaxel combined with pegvorhyaluronidase alfa (PEGPH20; PVHA) in patients with locally advanced or metastatic non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology (In Review).

3.    Trang M, Serogy JD, Van Wart SA, Bhavnani SM, Kim A, Gibbons JA, Ambrose PG, Rubino CM. Population pharmacokinetic analyses for plazomicin using pooled data from Phase 1, 2 and 3 clinical studies. Antimicrob Agents. 2019; 63(4): e02329-18.

www.ePD-LLC.com

Scott Van Wart:  Tel: (888) 714-6624 Ext. 1; Email: svanwart@ePD-LLC.com

Donald E. Mager:  Tel: (888) 714-6624 Ext. 2; Email: dmager@ePD-LLC.com